PL3348553T3 - Postacie krystaliczne modulatora receptora androgenowego - Google Patents

Postacie krystaliczne modulatora receptora androgenowego

Info

Publication number: PL3348553T3
Authority: PL; Poland
Prior art keywords: androgen receptor; crystalline forms; receptor modulator; modulator; androgen
Prior art date: 2012-06-07

Application number

PL18157435T

Other languages

English (en)

Inventor

Anna Dilhas

Ouathek Ouerfelli

Nicholas D. Smith

Mark R. Herbert

Original Assignee

Aragon Pharmaceuticals, Inc.

Sloan-Kettering Institute For Cancer Research

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-07

Filing date

2013-06-04

Publication date

2021-02-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3348553(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-06-04 Application filed by Aragon Pharmaceuticals, Inc., Sloan-Kettering Institute For Cancer Research filed Critical Aragon Pharmaceuticals, Inc.

2021-02-08 Publication of PL3348553T3 publication Critical patent/PL3348553T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Tropical Medicine & Parasitology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

PL18157435T 2012-06-07 2013-06-04 Postacie krystaliczne modulatora receptora androgenowego PL3348553T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261656888P	2012-06-07	2012-06-07
PCT/US2013/044116 WO2013184681A1 (en)	2012-06-07	2013-06-04	Crystalline forms of an androgen receptor modulator
EP13800681.2A EP2858985B1 (en)	2012-06-07	2013-06-04	Crystalline forms of an androgen receptor modulator
EP18157435.1A EP3348553B1 (en)	2012-06-07	2013-06-04	Crystalline forms of an androgen receptor modulator

Publications (1)

Publication Number	Publication Date
PL3348553T3 true PL3348553T3 (pl)	2021-02-08

Family

ID=49712550

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL13800681T PL2858985T3 (pl)	2012-06-07	2013-06-04	Postacie krystaliczne modulatora receptora androgenowego
PL19169275T PL3533792T3 (pl)	2012-06-07	2013-06-04	Postacie krystaliczne modulatora receptora androgenowego
PL18157435T PL3348553T3 (pl)	2012-06-07	2013-06-04	Postacie krystaliczne modulatora receptora androgenowego

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PL13800681T PL2858985T3 (pl)	2012-06-07	2013-06-04	Postacie krystaliczne modulatora receptora androgenowego
PL19169275T PL3533792T3 (pl)	2012-06-07	2013-06-04	Postacie krystaliczne modulatora receptora androgenowego

Country Status (45)

Country	Link
US (9)	US9481663B2 (pl)
EP (4)	EP3348553B1 (pl)
JP (3)	JP6182209B2 (pl)
KR (2)	KR102062024B1 (pl)
CN (3)	CN113135892A (pl)
AU (3)	AU2013271751B2 (pl)
BR (1)	BR112014030678A2 (pl)
CA (4)	CA3114726A1 (pl)
CL (1)	CL2014003331A1 (pl)
CO (1)	CO7240407A2 (pl)
CR (2)	CR20190331A (pl)
CY (4)	CY1120393T1 (pl)
DK (3)	DK3348553T3 (pl)
EA (3)	EA028791B1 (pl)
EC (1)	ECSP14030098A (pl)
ES (3)	ES2809738T3 (pl)
FR (1)	FR21C1050I2 (pl)
GT (1)	GT201400283A (pl)
HK (2)	HK1210175A1 (pl)
HR (3)	HRP20180902T1 (pl)
HU (4)	HUE038082T2 (pl)
IL (5)	IL320522A (pl)
IN (1)	IN2014DN10084A (pl)
LT (4)	LT3533792T (pl)
LU (1)	LUC00236I2 (pl)
ME (2)	ME03815B (pl)
MX (1)	MX356754B (pl)
MY (1)	MY187500A (pl)
NI (1)	NI201400142A (pl)
NL (1)	NL301144I2 (pl)
NO (1)	NO2021046I1 (pl)
NZ (2)	NZ702203A (pl)
PE (3)	PE20200725A1 (pl)
PH (2)	PH12014502714B1 (pl)
PL (3)	PL2858985T3 (pl)
PT (3)	PT2858985T (pl)
RS (3)	RS61988B1 (pl)
SG (3)	SG10201610249TA (pl)
SI (3)	SI3533792T1 (pl)
SM (3)	SMT201800311T1 (pl)
TR (1)	TR201808939T4 (pl)
TW (1)	TWI532732B (pl)
UA (2)	UA115665C2 (pl)
WO (1)	WO2013184681A1 (pl)
ZA (1)	ZA201500076B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008119015A2 (en)	2007-03-27	2008-10-02	Sloan-Kettering Institute For Cancer Research	Synthesis of thiohydantoins
PE20150099A1 (es)	2011-12-16	2015-01-30	Olema Pharmaceuticals Inc	Compuestos novedosos de benzopirano, composiciones y usos de los mismos
ES2809738T3 (es)	2012-06-07	2021-03-05	Aragon Pharmaceuticals Inc	Formas cristalinas de un modulador de receptor de andrógenos
WO2014043208A1 (en)	2012-09-11	2014-03-20	Medivation Prostate Therapeutics, Inc.	Formulations of enzalutamide
PT3305285T (pt)	2012-09-26	2020-11-24	Aragon Pharmaceuticals Inc	Antiandrogénios para o tratamento de cancro da próstata resistente à castração não metastático
JOP20200097A1 (ar)	2013-01-15	2017-06-16	Aragon Pharmaceuticals Inc	معدل مستقبل أندروجين واستخداماته
CN106795152B (zh) *	2014-08-26	2020-01-31	安斯达尔生物技术有限责任公司	蛋白激酶抑制剂
CR20170217A (es)	2014-12-05	2017-08-30	Aragon Pharmaceuticals Inc	Composiciones anticancerígenas
CA2969675C (en)	2014-12-05	2023-06-06	Aragon Pharmaceuticals, Inc.	Anticancer compositions
BR112017011788A2 (pt)	2014-12-05	2017-12-26	Aragon Pharmaceuticals Inc	composições anticâncer
WO2016100905A1 (en)	2014-12-19	2016-06-23	Lutron Electronics Co., Inc.	Multi-channel lighting fixture having multiple light-emitting diode drivers
TW201808287A (zh)	2016-06-03	2018-03-16	美商艾瑞岡醫藥公司	抗癌組成物
ES2952770T3 (es)	2016-12-13	2023-11-06	Watson Lab Inc	Formas de estado sólido de apalutamida
EP4438126A3 (en)	2017-10-16	2025-01-01	Aragon Pharmaceuticals, Inc.	Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2019135254A1 (en)	2018-01-02	2019-07-11	Mylan Laboratories Limited	Apalutamide polymorphs and their preparation thereof
WO2019242439A1 (zh) *	2018-06-20	2019-12-26	苏州科睿思制药有限公司	Arn-509的晶型及其制备方法和用途
WO2020049598A2 (en)	2018-09-08	2020-03-12	Cipla Limited	Apalutamide polymorphs
IT201900003839A1 (it)	2019-03-15	2020-09-15	Olon Spa	Sintesi di apalutamide amorfa stabile
WO2020234817A1 (en) *	2019-05-21	2020-11-26	Laurus Labs Limited	Polymorphic forms of apalutamide and its preparation thereof
IT201900010593A1 (it)	2019-07-01	2021-01-01	Dipharma Francis Srl	Forma cristallina di un inibitore di recettori degli androgeni
EP4017848A1 (en) *	2019-08-22	2022-06-29	Dr. Reddy's Laboratories Ltd.	Process for the preparation of apalutamide
IT201900015974A1 (it)	2019-09-10	2021-03-10	Olon Spa	Apalutamide cristallina stabile in forma pura e processo per la sua preparazione
CN110590740A (zh) *	2019-09-20	2019-12-20	武汉大学	一种阿帕鲁胺化合物及其药物制剂
WO2022049265A1 (en)	2020-09-04	2022-03-10	Synthon B.V.	Improved process for preparation of apalutamide
CN112679468A (zh) *	2021-01-05	2021-04-20	四川科伦药物研究院有限公司	阿帕他胺的晶体形式、制备方法和用途
WO2023143090A1 (zh) *	2022-01-25	2023-08-03	成都苑东生物制药股份有限公司	一种阿帕他胺溶剂化物新晶型及其制备方法
CN115536634B (zh) *	2022-10-17	2024-06-11	上海博悦生物科技有限公司	一种阿帕他胺的合成方法
CN116332907A (zh) *	2023-03-16	2023-06-27	奥锐特药业股份有限公司	一种无定形阿帕他胺的制备方法
WO2025153768A1 (en) *	2024-01-18	2025-07-24	Nanoform Finland Oyj	Composition comprising crystalline nanosized apalutamide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5323907A (en)	1992-06-23	1994-06-28	Multi-Comp, Inc.	Child resistant package assembly for dispensing pharmaceutical medications
US7709517B2 (en)	2005-05-13	2010-05-04	The Regents Of The University Of California	Diarylhydantoin compounds
CN101032483B (zh) *	2006-03-09	2011-05-04	陈德桂	调节雄激素受体活性的乙内酰脲衍生物及其应用
PL3412290T3 (pl)	2006-03-27	2021-09-06	The Regents Of The University Of California	Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
CA2648139A1 (en) *	2006-03-29	2007-11-08	The Regents Of The University Of California	Diaryl thiohydantoin compounds and their use in the treatment of hyperproliferative disorders
WO2008119015A2 (en) *	2007-03-27	2008-10-02	Sloan-Kettering Institute For Cancer Research	Synthesis of thiohydantoins
EA028869B1 (ru)	2010-02-16	2018-01-31	Арагон Фармасьютикалс, Инк.	Модуляторы рецептора андрогенов и их применение
ES2809738T3 (es)	2012-06-07	2021-03-05	Aragon Pharmaceuticals Inc	Formas cristalinas de un modulador de receptor de andrógenos
WO2019242439A1 (zh)	2018-06-20	2019-12-26	苏州科睿思制药有限公司	Arn-509的晶型及其制备方法和用途

2013
- 2013-06-04 ES ES18157435T patent/ES2809738T3/es active Active
- 2013-06-04 TW TW102119817A patent/TWI532732B/zh active
- 2013-06-04 CA CA3114726A patent/CA3114726A1/en active Pending
- 2013-06-04 CA CA2875767A patent/CA2875767C/en active Active
- 2013-06-04 ME MEP-2020-163A patent/ME03815B/me unknown
- 2013-06-04 CN CN202110417935.XA patent/CN113135892A/zh active Pending
- 2013-06-04 US US14/406,520 patent/US9481663B2/en active Active
- 2013-06-04 RS RS20210739A patent/RS61988B1/sr unknown
- 2013-06-04 SM SM20180311T patent/SMT201800311T1/it unknown
- 2013-06-04 DK DK18157435.1T patent/DK3348553T3/da active
- 2013-06-04 SG SG10201610249TA patent/SG10201610249TA/en unknown
- 2013-06-04 SI SI201331894T patent/SI3533792T1/sl unknown
- 2013-06-04 LT LTEP19169275.5T patent/LT3533792T/lt unknown
- 2013-06-04 HR HRP20180902TT patent/HRP20180902T1/hr unknown
- 2013-06-04 SI SI201331788T patent/SI3348553T1/sl unknown
- 2013-06-04 CN CN201610202980.2A patent/CN105693692A/zh active Pending
- 2013-06-04 PE PE2019002096A patent/PE20200725A1/es unknown
- 2013-06-04 IL IL320522A patent/IL320522A/en unknown
- 2013-06-04 PL PL13800681T patent/PL2858985T3/pl unknown
- 2013-06-04 CR CR20190331A patent/CR20190331A/es unknown
- 2013-06-04 CN CN201380041652.3A patent/CN104619692A/zh active Pending
- 2013-06-04 EP EP18157435.1A patent/EP3348553B1/en not_active Revoked
- 2013-06-04 HU HUE13800681A patent/HUE038082T2/hu unknown
- 2013-06-04 PL PL19169275T patent/PL3533792T3/pl unknown
- 2013-06-04 SG SG11201408140QA patent/SG11201408140QA/en unknown
- 2013-06-04 WO PCT/US2013/044116 patent/WO2013184681A1/en not_active Ceased
- 2013-06-04 IL IL267608A patent/IL267608B2/en unknown
- 2013-06-04 PT PT138006812T patent/PT2858985T/pt unknown
- 2013-06-04 EP EP21171579.2A patent/EP3922629A1/en active Pending
- 2013-06-04 LT LTEP18157435.1T patent/LT3348553T/lt unknown
- 2013-06-04 HK HK15111086.5A patent/HK1210175A1/xx unknown
- 2013-06-04 AU AU2013271751A patent/AU2013271751B2/en active Active
- 2013-06-04 ES ES13800681.2T patent/ES2670683T3/es active Active
- 2013-06-04 IN IN10084DEN2014 patent/IN2014DN10084A/en unknown
- 2013-06-04 MX MX2014015005A patent/MX356754B/es active IP Right Grant
- 2013-06-04 LT LTEP13800681.2T patent/LT2858985T/lt unknown
- 2013-06-04 ES ES19169275T patent/ES2875932T3/es active Active
- 2013-06-04 SM SM20200496T patent/SMT202000496T1/it unknown
- 2013-06-04 SM SM20210355T patent/SMT202100355T1/it unknown
- 2013-06-04 EP EP19169275.5A patent/EP3533792B1/en active Active
- 2013-06-04 SG SG10201610248SA patent/SG10201610248SA/en unknown
- 2013-06-04 HU HUE19169275A patent/HUE054595T2/hu unknown
- 2013-06-04 DK DK19169275.5T patent/DK3533792T3/da active
- 2013-06-04 PT PT181574351T patent/PT3348553T/pt unknown
- 2013-06-04 PL PL18157435T patent/PL3348553T3/pl unknown
- 2013-06-04 EA EA201492272A patent/EA028791B1/ru unknown
- 2013-06-04 EA EA201992010A patent/EA201992010A1/ru unknown
- 2013-06-04 RS RS20200913A patent/RS60617B1/sr unknown
- 2013-06-04 JP JP2015516121A patent/JP6182209B2/ja active Active
- 2013-06-04 PE PE2014002383A patent/PE20150631A1/es active IP Right Grant
- 2013-06-04 PE PE2020000234A patent/PE20200795A1/es unknown
- 2013-06-04 UA UAA201500086A patent/UA115665C2/uk unknown
- 2013-06-04 KR KR1020157000266A patent/KR102062024B1/ko active Active
- 2013-06-04 PT PT191692755T patent/PT3533792T/pt unknown
- 2013-06-04 RS RS20180680A patent/RS57370B1/sr unknown
- 2013-06-04 HU HUE18157435A patent/HUE050357T2/hu unknown
- 2013-06-04 CA CA3008345A patent/CA3008345C/en active Active
- 2013-06-04 TR TR2018/08939T patent/TR201808939T4/tr unknown
- 2013-06-04 SI SI201331010T patent/SI2858985T1/sl unknown
- 2013-06-04 KR KR1020197033592A patent/KR102195916B1/ko active Active
- 2013-06-04 NZ NZ702203A patent/NZ702203A/en unknown
- 2013-06-04 UA UAA201702779A patent/UA123142C2/uk unknown
- 2013-06-04 DK DK13800681.2T patent/DK2858985T3/en active
- 2013-06-04 EA EA201791592A patent/EA033956B1/ru unknown
- 2013-06-04 EP EP13800681.2A patent/EP2858985B1/en active Active
- 2013-06-04 ME MEP-2018-158A patent/ME03081B/me unknown
- 2013-06-04 CA CA3055660A patent/CA3055660A1/en not_active Abandoned
- 2013-06-04 BR BR112014030678A patent/BR112014030678A2/pt not_active Application Discontinuation
- 2013-06-04 NZ NZ717683A patent/NZ717683A/en unknown
- 2013-06-04 MY MYPI2014703627A patent/MY187500A/en unknown
2014
- 2014-12-01 CR CR20140549A patent/CR20140549A/es unknown
- 2014-12-04 IL IL236055A patent/IL236055A0/en unknown
- 2014-12-04 NI NI201400142A patent/NI201400142A/es unknown
- 2014-12-04 PH PH12014502714A patent/PH12014502714B1/en unknown
- 2014-12-05 EC ECIEPI201430098A patent/ECSP14030098A/es unknown
- 2014-12-05 CL CL2014003331A patent/CL2014003331A1/es unknown
- 2014-12-05 GT GT201400283A patent/GT201400283A/es unknown
- 2014-12-09 CO CO14270612A patent/CO7240407A2/es unknown
2015
- 2015-01-06 ZA ZA2015/00076A patent/ZA201500076B/en unknown
2016
- 2016-07-26 PH PH12016501470A patent/PH12016501470B1/en unknown
- 2016-09-12 US US15/262,522 patent/US9994545B2/en active Active
- 2016-12-19 HK HK16114389.2A patent/HK1226066A1/zh unknown
2017
- 2017-01-17 AU AU2017200298A patent/AU2017200298B2/en active Active
- 2017-02-15 JP JP2017025746A patent/JP6345821B2/ja active Active
- 2017-12-22 AU AU2017279807A patent/AU2017279807B2/en active Active
2018
- 2018-05-09 US US15/975,449 patent/US10308630B2/en active Active
- 2018-05-23 JP JP2018098638A patent/JP2018141009A/ja active Pending
- 2018-05-31 IL IL259738A patent/IL259738B/en active IP Right Grant
- 2018-07-06 CY CY20181100712T patent/CY1120393T1/el unknown
2019
- 2019-04-15 US US16/384,002 patent/US10526310B2/en active Active
- 2019-07-10 US US16/507,780 patent/US10556882B2/en active Active
- 2019-12-11 US US16/710,785 patent/US10766875B2/en active Active
2020
- 2020-06-15 IL IL275413A patent/IL275413A/en unknown
- 2020-07-29 US US16/942,069 patent/US10934271B2/en active Active
- 2020-08-31 HR HRP20201387TT patent/HRP20201387T1/hr unknown
- 2020-09-23 CY CY20201100901T patent/CY1123427T1/el unknown
2021
- 2021-01-26 US US17/158,806 patent/US12018008B2/en active Active
- 2021-06-08 HR HRP20210909TT patent/HRP20210909T1/hr unknown
- 2021-07-02 CY CY20211100595T patent/CY1124831T1/el unknown
- 2021-11-02 NO NO2021046C patent/NO2021046I1/no unknown
- 2021-11-02 LU LU00236C patent/LUC00236I2/fr unknown
- 2021-11-03 FR FR21C1050C patent/FR21C1050I2/fr active Active
- 2021-11-03 LT LTPA2021525C patent/LTC3533792I2/lt unknown
- 2021-11-03 NL NL301144C patent/NL301144I2/nl unknown
- 2021-11-04 HU HUS2100047C patent/HUS2100047I1/hu unknown
- 2021-11-04 CY CY2021032C patent/CY2021032I2/el unknown
2024
- 2024-05-13 US US18/662,345 patent/US20250092011A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HUE054595T2 (hu)	2021-09-28
MY187500A (en)	2021-09-24
TW201402561A (zh)	2014-01-16
SI3348553T1 (sl)	2020-11-30
CA2875767A1 (en)	2013-12-12
RS61988B1 (sr)	2021-07-30
EA201492272A1 (ru)	2015-05-29
US20190241539A1 (en)	2019-08-08
IL267608A (en)	2019-08-29
PE20200795A1 (es)	2020-08-10
HUE038082T2 (hu)	2018-09-28
US12018008B2 (en)	2024-06-25
RS60617B1 (sr)	2020-09-30
MX356754B (es)	2018-06-11
EP3533792A1 (en)	2019-09-04
PE20200725A1 (es)	2020-07-21
KR102195916B1 (ko)	2020-12-30
MX2014015005A (es)	2015-09-04
KR20150021993A (ko)	2015-03-03
TWI532732B (zh)	2016-05-11
LUC00236I2 (pl)	2025-02-03
LT3533792T (lt)	2021-07-26
LT2858985T (lt)	2018-09-25
AU2013271751B2 (en)	2017-02-23
CN104619692A (zh)	2015-05-13
EP3348553B1 (en)	2020-07-08
SI2858985T1 (sl)	2018-12-31
ZA201500076B (en)	2016-10-26
CY1120393T1 (el)	2019-07-10
CR20140549A (es)	2015-04-06
FR21C1050I1 (fr)	2021-12-10
IL259738A (en)	2018-07-31
HRP20201387T1 (hr)	2020-11-27
CA3055660A1 (en)	2013-12-12
HK1210175A1 (en)	2016-04-15
US20210163441A1 (en)	2021-06-03
PL3533792T3 (pl)	2021-11-29
FR21C1050I2 (fr)	2024-05-24
US20190330182A1 (en)	2019-10-31
EP3922629A1 (en)	2021-12-15
EA033956B1 (ru)	2019-12-13
ES2670683T3 (es)	2018-05-31
HUE050357T2 (hu)	2020-11-30
PT2858985T (pt)	2018-07-10
US20170001977A1 (en)	2017-01-05
US20250092011A1 (en)	2025-03-20
ES2809738T3 (es)	2021-03-05
HK1226066A1 (zh)	2017-09-22
JP2018141009A (ja)	2018-09-13
CA3008345A1 (en)	2013-12-12
IL320522A (en)	2025-06-01
EA201992010A1 (ru)	2020-01-24
IN2014DN10084A (pl)	2015-08-21
NZ702203A (en)	2016-09-30
UA123142C2 (uk)	2021-02-24
DK2858985T3 (en)	2018-05-28
CR20190331A (es)	2019-11-12
IL259738B (en)	2021-06-30
SG11201408140QA (en)	2015-01-29
AU2017200298B2 (en)	2017-09-28
GT201400283A (es)	2017-07-03
SI3533792T1 (sl)	2021-11-30
PT3348553T (pt)	2020-09-28
WO2013184681A1 (en)	2013-12-12
LTPA2021525I1 (pl)	2021-11-25
CY2021032I1 (pl)	2022-03-24
US10526310B2 (en)	2020-01-07
EP2858985B1 (en)	2018-04-18
NI201400142A (es)	2016-12-02
US10934271B2 (en)	2021-03-02
CN113135892A (zh)	2021-07-20
EA028791B1 (ru)	2017-12-29
JP2015518890A (ja)	2015-07-06
US20200354335A1 (en)	2020-11-12
HRP20180902T1 (hr)	2018-08-24
US20180258067A1 (en)	2018-09-13
CA2875767C (en)	2018-08-14
AU2017279807B2 (en)	2018-11-08
AU2017279807A1 (en)	2018-01-25
KR20190132543A (ko)	2019-11-27
ECSP14030098A (es)	2016-01-29
NZ717683A (en)	2018-04-27
AU2013271751A1 (en)	2014-12-18
ME03081B (me)	2019-01-20
CL2014003331A1 (es)	2016-03-04
JP6182209B2 (ja)	2017-08-16
IL236055A0 (en)	2015-02-01
PH12014502714A1 (en)	2015-02-02
JP6345821B2 (ja)	2018-06-20
CA3114726A1 (en)	2013-12-12
PH12014502714B1 (en)	2015-02-02
HRP20210909T1 (hr)	2021-09-03
US10556882B2 (en)	2020-02-11
SG10201610249TA (en)	2017-02-27
IL275413A (en)	2020-07-30
EA201791592A1 (ru)	2018-01-31
ES2875932T3 (es)	2021-11-11
PH12016501470B1 (en)	2021-12-10
BR112014030678A2 (pt)	2017-06-27
CA3008345C (en)	2019-10-22
IL267608B1 (en)	2025-06-01
CN105693692A (zh)	2016-06-22
EP3348553A1 (en)	2018-07-18
DK3348553T3 (da)	2020-07-27
US10766875B2 (en)	2020-09-08
PH12016501470A1 (en)	2017-07-10
ME03815B (me)	2021-04-20
US9994545B2 (en)	2018-06-12
PE20150631A1 (es)	2015-05-11
AU2017200298A1 (en)	2017-02-02
PL2858985T3 (pl)	2018-09-28
LTC3533792I2 (pl)	2024-07-10
US10308630B2 (en)	2019-06-04
IL267608B2 (en)	2025-10-01
KR102062024B1 (ko)	2020-01-03
SMT202000496T1 (it)	2020-11-10
TR201808939T4 (tr)	2018-07-23
NL301144I2 (nl)	2025-03-20
CO7240407A2 (es)	2015-04-17
DK3533792T3 (da)	2021-06-28
JP2017178923A (ja)	2017-10-05
LT3348553T (lt)	2020-09-25
CY1123427T1 (el)	2021-12-31
PT3533792T (pt)	2021-06-07
NO2021046I1 (no)	2021-11-02
SMT201800311T1 (it)	2018-07-17
US9481663B2 (en)	2016-11-01
RS57370B1 (sr)	2018-08-31
CY1124831T1 (el)	2022-03-24
UA115665C2 (uk)	2017-12-11
EP3533792B1 (en)	2021-05-05
SG10201610248SA (en)	2017-02-27
US20150133481A1 (en)	2015-05-14
EP2858985A4 (en)	2016-05-25
SMT202100355T1 (it)	2021-07-12
EP2858985A1 (en)	2015-04-15
HUS2100047I1 (hu)	2021-11-29
US20200115361A1 (en)	2020-04-16
CY2021032I2 (el)	2022-03-24

Publication	Publication Date	Title
IL275413A (en)	2020-07-30	Crystal forms of an androgen receptor modulator
IL262218A (en)	2018-11-29	Modulation of androgen receptor expression
IL266446A (en)	2019-06-30	Androgen synthesis modulators
AP2014007548A0 (en)	2014-03-31	Selective androgen receptor modulators
ZA201500096B (en)	2017-07-26	Indolecarbonitriles as selective androgen receptor modulators
IL239076A0 (en)	2015-07-30	Novel and selective androgen receptor modulators